Compare GSK & ELV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSK | ELV |
|---|---|---|
| Founded | 1715 | 1944 |
| Country | United Kingdom | United States |
| Employees | 66841 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 108.7B | 85.7B |
| IPO Year | N/A | 2001 |
| Metric | GSK | ELV |
|---|---|---|
| Price | $51.88 | $390.86 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 19 |
| Target Price | N/A | ★ $383.56 |
| AVG Volume (30 Days) | ★ 3.6M | 1.4M |
| Earning Date | 04-29-2026 | 04-22-2026 |
| Dividend Yield | ★ 3.40% | 1.83% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 8.00 |
| Revenue | N/A | ★ $199,125,000,000.00 |
| Revenue This Year | $6.99 | N/A |
| Revenue Next Year | $4.19 | $3.07 |
| P/E Ratio | ★ $32.75 | $49.70 |
| Revenue Growth | N/A | ★ 12.49 |
| 52 Week Low | $35.45 | $273.71 |
| 52 Week High | $61.70 | $426.98 |
| Indicator | GSK | ELV |
|---|---|---|
| Relative Strength Index (RSI) | 51.61 | 49.39 |
| Support Level | $51.55 | $384.30 |
| Resistance Level | $59.97 | $408.00 |
| Average True Range (ATR) | 0.80 | 11.28 |
| MACD | 0.29 | -3.29 |
| Stochastic Oscillator | 68.55 | 12.20 |
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 45 million medical members at the end of 2025. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states in government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.